AXA boosted its holdings in shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) by 12.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 265,408 shares of the biopharmaceutical company’s stock after purchasing an additional 28,755 shares during the period. AXA owned approximately 0.62% of Ultragenyx Pharmaceutical worth $14,136,000 as of its most recent filing with the SEC.
A number of other institutional investors have also modified their holdings of RARE. Dimensional Fund Advisors LP raised its position in Ultragenyx Pharmaceutical by 51.6% during the first quarter. Dimensional Fund Advisors LP now owns 17,092 shares of the biopharmaceutical company’s stock worth $1,158,000 after acquiring an additional 5,816 shares during the last quarter. Aperio Group LLC raised its position in Ultragenyx Pharmaceutical by 8.4% during the second quarter. Aperio Group LLC now owns 3,851 shares of the biopharmaceutical company’s stock worth $239,000 after acquiring an additional 299 shares during the last quarter. Russell Investments Group Ltd. raised its position in Ultragenyx Pharmaceutical by 11.4% during the second quarter. Russell Investments Group Ltd. now owns 31,184 shares of the biopharmaceutical company’s stock worth $1,937,000 after acquiring an additional 3,195 shares during the last quarter. Sei Investments Co. acquired a new position in Ultragenyx Pharmaceutical during the second quarter worth about $125,000. Finally, TD Asset Management Inc. raised its position in Ultragenyx Pharmaceutical by 4.4% during the second quarter. TD Asset Management Inc. now owns 37,728 shares of the biopharmaceutical company’s stock worth $2,343,000 after acquiring an additional 1,600 shares during the last quarter. 94.10% of the stock is currently owned by institutional investors.
RARE has been the subject of a number of analyst reports. Canaccord Genuity set a $80.00 price objective on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday, December 5th. Barclays boosted their target price on shares of Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the company an “equal weight” rating in a report on Tuesday, December 5th. Zacks Investment Research upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, November 8th. BidaskClub downgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, December 12th. Finally, Wedbush upgraded shares of Ultragenyx Pharmaceutical from a “neutral” rating to an “outperform” rating and set a $62.00 price objective for the company in a research note on Thursday, September 14th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Ultragenyx Pharmaceutical presently has an average rating of “Hold” and a consensus target price of $72.40.
Shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) traded down $0.89 during trading hours on Thursday, hitting $48.17. 376,653 shares of the company’s stock were exchanged, compared to its average volume of 417,994. The firm has a market capitalization of $2,050.00, a PE ratio of -6.91 and a beta of 1.83. Ultragenyx Pharmaceutical Inc has a 52 week low of $43.14 and a 52 week high of $91.35.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) EPS for the quarter, hitting the consensus estimate of ($1.87). The firm had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.02 million. The firm’s revenue was up 81.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.64) EPS. sell-side analysts predict that Ultragenyx Pharmaceutical Inc will post -7.3 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/11/axa-acquires-28755-shares-of-ultragenyx-pharmaceutical-inc-rare.html.
Ultragenyx Pharmaceutical Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.